Literature DB >> 26908626

Genetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration.

Chan Chung1, Prasanth Puthanveetil1, Daniel S Ory2, Andrew P Lieberman3.   

Abstract

Niemann-Pick C1 (NPC) disease, an autosomal recessive lipid trafficking disorder caused by loss-of-function mutations in the NPC1 gene, is characterized by progressive neurodegeneration resulting in cognitive impairment, ataxia and early death. Little is known about the cellular pathways leading to neuron loss. Here, we studied the effects of diminishing expression of cystatin B, an endogenous inhibitor of cathepsins B, H and L, on the development of NPC neuropathology. We show that decreased expression of cystatin B in patient fibroblasts enhances cathepsin activity. Deletion of the encoding Cstb gene in Npc1-deficient mice resulted in striking deleterious effects, particularly within the cerebellum where diffuse loss of Purkinje cells was observed in young mice. This severe pathology occurred through cell autonomous mechanisms that triggered Purkinje cell death. Moreover, our analyses demonstrated the mislocalization of lysosomal cathepsins within the cytosol of Npc1-deficient Purkinje cells. We provide evidence that this may be a consequence of damage to lysosomal membranes by reactive oxygen species (ROS), leading to the leakage of lysosomal contents that culminates in apoptotic cell death. Consistent with this notion, toxicity from ROS was attenuated in an NPC cell model by cystatin B over-expression or pharmacological inhibition of cathepsin B. The observation that Npc1 and Cstb deletion genetically interact to potently enhance the degenerative phenotype of the NPC cerebellum provides strong support for the notion that lysosomal membrane permeabilization contributes to cerebellar degeneration in NPC disease.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26908626      PMCID: PMC4787909          DOI: 10.1093/hmg/ddw025

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  62 in total

Review 1.  The cystatins: protein inhibitors of cysteine proteinases.

Authors:  V Turk; W Bode
Journal:  FEBS Lett       Date:  1991-07-22       Impact factor: 4.124

2.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease.

Authors:  Matthew J Elrick; Ting Yu; Chan Chung; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2012-08-07       Impact factor: 6.150

4.  Cathepsin B contributes to traumatic brain injury-induced cell death through a mitochondria-mediated apoptotic pathway.

Authors:  Cheng-Liang Luo; Xi-Ping Chen; Rui Yang; Yu-Xia Sun; Qian-Qian Li; Hai-Jun Bao; Qiang-Qiang Cao; Hong Ni; Zheng-Hong Qin; Lu-Yang Tao
Journal:  J Neurosci Res       Date:  2010-10       Impact factor: 4.164

5.  Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease.

Authors:  Vivian Hook; Mark Kindy; Gregory Hook
Journal:  Biol Chem       Date:  2007-02       Impact factor: 3.915

Review 6.  Cysteine cathepsins in neurological disorders.

Authors:  Anja Pišlar; Janko Kos
Journal:  Mol Neurobiol       Date:  2013-11-15       Impact factor: 5.590

7.  VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation.

Authors:  Sung-Hee Chang; Keizo Kanasaki; Vasilena Gocheva; Galia Blum; Jay Harper; Marsha A Moses; Shou-Ching Shih; Janice A Nagy; Johanna Joyce; Matthew Bogyo; Raghu Kalluri; Harold F Dvorak
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

8.  Kinetics of the pH-induced inactivation of human cathepsin L.

Authors:  B Turk; I Dolenc; V Turk; J G Bieth
Journal:  Biochemistry       Date:  1993-01-12       Impact factor: 3.162

Review 9.  Neuronal and microglial cathepsins in aging and age-related diseases.

Authors:  Hiroshi Nakanishi
Journal:  Ageing Res Rev       Date:  2003-10       Impact factor: 10.895

10.  Posttranslational processing and modification of cathepsins and cystatins.

Authors:  Nobuhiko Katunuma
Journal:  J Signal Transduct       Date:  2010-12-16
View more
  15 in total

1.  Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions.

Authors:  Michael C Yoon; Angelo Solania; Zhenze Jiang; Mitchell P Christy; Sonia Podvin; Charles Mosier; Christopher B Lietz; Gen Ito; William H Gerwick; Dennis W Wolan; Gregory Hook; Anthony J O'Donoghue; Vivian Hook
Journal:  ACS Chem Biol       Date:  2021-08-20       Impact factor: 4.634

2.  Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease.

Authors:  Kanagaraj Subramanian; Navin Rauniyar; Mathieu Lavalleé-Adam; John R Yates; William E Balch
Journal:  Mol Cell Proteomics       Date:  2017-08-31       Impact factor: 5.911

Review 3.  Lysosome and endoplasmic reticulum quality control pathways in Niemann-Pick type C disease.

Authors:  Mark L Schultz; Kelsey L Krus; Andrew P Lieberman
Journal:  Brain Res       Date:  2016-03-26       Impact factor: 3.252

4.  NPC1-mTORC1 Signaling Couples Cholesterol Sensing to Organelle Homeostasis and Is a Targetable Pathway in Niemann-Pick Type C.

Authors:  Oliver B Davis; Hijai R Shin; Chun-Yan Lim; Emma Y Wu; Matthew Kukurugya; Claire F Maher; Rushika M Perera; M Paulina Ordonez; Roberto Zoncu
Journal:  Dev Cell       Date:  2020-12-11       Impact factor: 13.417

5.  Lipid-induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders.

Authors:  Enrique Gabandé-Rodríguez; Azucena Pérez-Cañamás; Beatriz Soto-Huelin; Daniel N Mitroi; Sara Sánchez-Redondo; Elena Martínez-Sáez; César Venero; Héctor Peinado; María Dolores Ledesma
Journal:  EMBO J       Date:  2018-12-07       Impact factor: 11.598

6.  Penetrating Traumatic Brain Injury Triggers Dysregulation of Cathepsin B Protein Levels Independent of Cysteine Protease Activity in Brain and Cerebral Spinal Fluid.

Authors:  Angela M Boutté; Vivian Hook; Bharani Thangavelu; George Anis Sarkis; Brittany N Abbatiello; Gregory Hook; J Steven Jacobsen; Claudia S Robertson; Janice Gilsdorf; Zhihui Yang; Kevin K W Wang; Deborah A Shear
Journal:  J Neurotrauma       Date:  2020-04-02       Impact factor: 5.269

7.  TDP-43 proteinopathy occurs independently of autophagic substrate accumulation and underlies nuclear defects in Niemann-Pick C disease.

Authors:  Elaine A Liu; Erika Mori; Fuko Hamasaki; Andrew P Lieberman
Journal:  Neuropathol Appl Neurobiol       Date:  2021-06-15       Impact factor: 8.090

8.  Individualized management of genetic diversity in Niemann-Pick C1 through modulation of the Hsp70 chaperone system.

Authors:  Chao Wang; Samantha M Scott; Shuhong Sun; Pei Zhao; Darren M Hutt; Hao Shao; Jason E Gestwicki; William E Balch
Journal:  Hum Mol Genet       Date:  2020-01-01       Impact factor: 5.121

9.  DNA Checkpoint and Repair Factors Are Nuclear Sensors for Intracellular Organelle Stresses-Inflammations and Cancers Can Have High Genomic Risks.

Authors:  Huihong Zeng; Gayani K Nanayakkara; Ying Shao; Hangfei Fu; Yu Sun; Ramon Cueto; William Y Yang; Qian Yang; Haitao Sheng; Na Wu; Luqiao Wang; Wuping Yang; Hongping Chen; Lijian Shao; Jianxin Sun; Xuebin Qin; Joon Y Park; Konstantinos Drosatos; Eric T Choi; Qingxian Zhu; Hong Wang; Xiaofeng Yang
Journal:  Front Physiol       Date:  2018-05-11       Impact factor: 4.566

10.  The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.

Authors:  Rami A Ballout; Dmitri Sviridov; Michael I Bukrinsky; Alan T Remaley
Journal:  FASEB J       Date:  2020-05-05       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.